Selective MEK Inhibitors via ATP Site Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective small molecules that selectively inhibit MEK activity, which is constitutively activated in various hyperproliferative diseases such as cancers, leading to inadequate treatment options.
Innovation Solution
Development of specific compounds, including those of Formula I, which selectively inhibit MEK by modulating ATP binding and association with ERK, offering ATP-competitive inhibition.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used, then treatment of hyperproliferative diseases is provided, but selective inhibition of MEK activity is insufficient
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of small molecules to achieve selective MEK inhibition. Specifically, the compounds of Formula I incorporate particular substituent patterns (R1-R8 groups) and structural features (n=0,1,2,3) that optimize binding affinity to MEK's ATP site while maintaining selectivity against other kinases, thereby improving the reliability of MEK inhibition as a therapeutic parameter
2Reliability
If small molecules are designed to inhibit MEK, then selective inhibition is achieved, but availability of effective compounds is limited
Solution Approach 1:
The patent applies universality by creating a broad chemical series (Formula I with multiple R-group variations) that all share the common function of selective MEK inhibition. The core imidazoquinoline structure with systematic substituent variations (different R1-R8 groups) provides a universal scaffold that can be adapted to generate multiple effective compounds, thereby increasing the quantity of available therapeutic agents while maintaining selective MEK inhibition
Data Source
Figure 1
AI summary
The present invention relates to compounds of formula I in which n, R1, R2, R3a, R4 and R5 are defined in the Summary of the Invention; capable of inhibiting the activity of MEK. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of hyperproliferative diseases like cancer.